Seegene said today that it has partnered with Korea's Samsung Medical Center to co-develop molecular diagnostics for cancer.

Under the partnership, Seegene will contribute its dual-priming oligonucleotide, or DPO, PCR and real amplicon detection, or READ, PCR, technologies to develop tests for genetic mutations indicative of certain cancers.

Seegene will also incorporate its technologies into tests for drug resistance and single nucleotide polymorphism detection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.